(Rac) -ErSO-DFP

(Rac) -ErSO-DFP is a selective ERα biomodulator that exhibits potent anti-tumor activity against ERα-positive breast cancers, including therapy-resistant forms. It functions by hyperactivating the anticipatory unfolded protein response (a-UPR) pathway, leading to rapid tumor cell death. This mechanism has been validated in both in vitro cell studies and in vivo xenograft models, highlighting its research utility in oncology and cancer pharmacology.